Gut Microbiome Pathways May Predict Response to Nivolumab for Gastric Cancer
The investigation concluded that gut microbiome pathways associated with bacterial invasion of epithelial cells may predict response to nivolumab treatment in these patients. The trial also found that gastric cancer patients who responded to nivolumab treatment had a more diverse gut microbiome than did their counterparts who did not respond to the immune checkpoint inhibitor.